Beacon Therapeutics (USA) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/01/2024
Beacon Therapeutics (USA) Fair Value Forecast for 2023 - 2025 - 2030
In the last year, Beacon Therapeutics (USA)'s Price has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that Beacon Therapeutics (USA)'s Fair Value will increase in the upcoming year, reaching $0.00. This would represent an increase of 100.00%. Over the next six years, experts predict that Beacon Therapeutics (USA)'s Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$162.64 | Buy/Sell | $178.42 | 14.36% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$273.94 | Buy/Sell | $303.65 | 16.63% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.20 | Buy/Sell | $87.82 | 22.70% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$214.82 | Buy/Sell | $299.62 | 34.30% |
Beacon Therapeutics (USA) Revenue Forecast for 2023 - 2025 - 2030
Beacon Therapeutics (USA)'s Revenue has decreased by 86.53% In the last two years, from $2.45M to $330.00k. Analysts predict that Beacon Therapeutics (USA)'s Revenue will increase in the upcoming year, reaching $872.34k. This would represent an increase of 164.35%. Over the next eight years, experts predict that Beacon Therapeutics (USA)'s Revenue will grow at a rate of 303.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$80.76 | Buy/Sell | $111.56 | 36.21% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$52.05 | Buy/Sell | $77.05 | 48.32% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$79.58 | Buy/Sell | $34.00 | 44.51% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$91.34 | Buy/Sell | $85.71 | 9.48% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$9.99 | Buy/Sell | $17.90 | 100.20% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$11.78 | Buy/Sell | $20.42 | 116.47% |
Beacon Therapeutics (USA) EBITDA Forecast for 2023 - 2025 - 2030
Beacon Therapeutics (USA)'s EBITDA has grown in the last two years, jumping from $-45.61M to $-64.66M – an increase of 41.77%. For the next year, 0 analysts project Beacon Therapeutics (USA)'s EBITDA to drop by 14.56%, reaching $-55.24M. By 2030, professionals believe that Beacon Therapeutics (USA)'s EBITDA will decrease by 13.39%, reaching $-56.00M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$16.71 | Buy/Sell | $33.78 | 78.64% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$22.62 | Buy/Sell | $52.00 | 134.31% |
Beacon Therapeutics (USA) EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Beacon Therapeutics (USA)'s EBIT has increased by 40.99%, going from $-46.94M to $-66.18M. According to 0 prominent analysts, Beacon Therapeutics (USA)'s EBIT will fall by 14.35% in the next year, reaching $-56.68M. By 2030, professionals believe that Beacon Therapeutics (USA)'s EBIT will decrease by 13.22%, reaching $-57.43M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$37.42 | Buy/Sell | $63.29 | 105.77% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$45.87 | Buy/Sell | $42.58 | 19.90% |
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.40 | Buy/Sell | $9.94 | 110.94% |
Beacon Therapeutics (USA) EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last year, Beacon Therapeutics (USA)'s EPS has seen an increase, rising from $0.00 to $0.00. This represents a growth of 100.00%. Analysts predict that Beacon Therapeutics (USA)'s EPS will increase in the upcoming year, reaching $0.00. This would represent an increase of 100.00%. Over the next six years, experts predict that Beacon Therapeutics (USA)'s EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.37 | Buy/Sell | $25.00 | 115.48% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$32.50 | Buy/Sell | $40.00 | 33.85% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.52 | Buy/Sell | $6.00 | 22.70% |
Site Navigation
.jpg)